A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Learn more about Aprea Therapeutics Inc’s (APRE) stock grades for Value, Growth, Momentum, Estimate Revisions and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Jack Gilleland
| Share Statistics | APRE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7.7 | $252.6 | 5% |
|
| Shares Out (Mil) | 14.7 | 52.3 | 26% |
|
| Institutional Ownership | 46.6% | 92.1% | 21% |
|
| Float (Mil) | 7.4 | 40.2 | 16% |
|
| Beta | 1.56 | 0.95 | 84% |
|
| Avg Daily Volume (000s) | 45 | 455 | 27% |
|
| Price Change (52-week) |
(66.3%) | 52.9% | 10% |
|
| Growth | APRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 25.1% | (9.9%) | 80% |
|
| EPS (5yr) | 48.0% | 16.0% | 92 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 49.6% | (15.6%) | 93% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 3 | 3 | |
| Current EPS | ($0.220) | ($0.830) | ($0.790) | |
| Month Ago EPS | ($0.220) | ($0.830) | ($0.790) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.240) | ($0.805) | ($0.660) | |
| Year/Year Chg | (1.8%) | (56.9%) | (56.4%) | |
| Financials | APRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $38 | 0% |
|
| Net Income (TTM) (Mil) | ($12) | ($43) | 28% |
|
| EPS (TTM) | ($1.372) | ($1.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($31) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($38) | $180 | 1% |
|
| Valuation | APRE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.18 | 2.56 | 3% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | APRE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (35.2%) | (49.8%) | 15% |
|
| ROE | (41.8%) | (55.5%) | 17% |
|
| Liabilities to Assets | 11.1% | 30.3% | 6% |
|
| F-Score | 2 | 3 | 7% |
|
Aprea Therapeutics, Inc. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
